Skip to main content

Table 3 Impact of IPO13 polymorphisms on methacholine hyperresponsiveness (PC20) in childhood asthma

From: Importin-13 genetic variation is associated with improved airway responsiveness in childhood asthma

    

Treatment-stratified analysis

SNP

Genic location

MAF

All subjects (n = 654)

Budesonide (n = 214)

Placebo or Nedocramil (n = 440)

rs6671164

5' genomic

0.223

0.002

-

0.004

rs4448553

5' genomic

0.223

0.02

-

0.01

rs1990150

Intron 1

0.148

0.02

-

0.04

rs2240447

Exon 2

0.224

-

-

-

rs2486014

Intron 2

0.097

0.04

-

-

rs2301993

Intron 12

0.222

0.002

-

0.001

rs2301992

Intron 13

0.049

0.02

-

0.03

rs1636879

Intron 14

0.102

0.02

-

0.04

rs7412307

3' genomic

0.184

0.02

-

0.04

rs2428953

3' genomic

0.11

0.002

-

0.005

  1. Results based on repeated-measures analysis assuming an additive genetic model with log10-PC20. All analyses are adjusted for PC20 prior to treatment randomization, age, gender, height, study center and study visit. All-subject analysis adjusted for treatment-arm assignment (budesonide vs. other). MAF = minor allele frequency. "-" denotes nominal p-value > 0.05.